biotech / news / / Reuters
Lilly expects to earn $35.50 to $37.00 per share on an adjusted basis in 2026.
Lilly raised its 2026 adjusted profit forecast to $35.50-$37.00 per share, exceeding analyst estimates.
KEY POINTS
- Lilly overtook Novo as the market share leader for GLP-1s in international (ex-US) markets.
- Sales of Mounjaro reached $8.7 billion, over $1 billion higher than expectations.
- Foundayo's U.S. launch saw 3,707 prescriptions in one week, falling short of analyst expectations.
COMPANIES
Summarized by Newsio from Reuters. How we summarize →